NZ596171A - Hiv vaccine based on targeting maximized gag and nef to dendritic cells - Google Patents

Hiv vaccine based on targeting maximized gag and nef to dendritic cells

Info

Publication number
NZ596171A
NZ596171A NZ596171A NZ59617109A NZ596171A NZ 596171 A NZ596171 A NZ 596171A NZ 596171 A NZ596171 A NZ 596171A NZ 59617109 A NZ59617109 A NZ 59617109A NZ 596171 A NZ596171 A NZ 596171A
Authority
NZ
New Zealand
Prior art keywords
nef
dendritic cells
vaccine based
hiv vaccine
gag
Prior art date
Application number
NZ596171A
Other languages
English (en)
Inventor
Jacques F Banchereau
Original Assignee
Baylor Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Inst filed Critical Baylor Res Inst
Publication of NZ596171A publication Critical patent/NZ596171A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ596171A 2008-07-16 2009-07-16 Hiv vaccine based on targeting maximized gag and nef to dendritic cells NZ596171A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8123408P 2008-07-16 2008-07-16

Publications (1)

Publication Number Publication Date
NZ596171A true NZ596171A (en) 2012-05-25

Family

ID=41551022

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ596171A NZ596171A (en) 2008-07-16 2009-07-16 Hiv vaccine based on targeting maximized gag and nef to dendritic cells
NZ594540A NZ594540A (en) 2008-07-16 2009-07-16 Hiv vaccine based on targeting maximized gag and nef antigen to dendritic cells using antibodies
NZ590628A NZ590628A (en) 2008-07-16 2009-07-16 Hiv vaccine based on targeting maximized gag and nef to dendritic cells

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ594540A NZ594540A (en) 2008-07-16 2009-07-16 Hiv vaccine based on targeting maximized gag and nef antigen to dendritic cells using antibodies
NZ590628A NZ590628A (en) 2008-07-16 2009-07-16 Hiv vaccine based on targeting maximized gag and nef to dendritic cells

Country Status (19)

Country Link
US (1) US9109011B2 (enExample)
EP (3) EP2307048A4 (enExample)
JP (2) JP5984388B2 (enExample)
KR (2) KR20110036618A (enExample)
CN (1) CN102625714B (enExample)
AP (1) AP2011005541A0 (enExample)
AU (1) AU2009270771B2 (enExample)
BR (1) BRPI0915915A2 (enExample)
CA (1) CA2730742C (enExample)
DK (1) DK2966091T3 (enExample)
ES (2) ES2685823T3 (enExample)
IL (1) IL210646A0 (enExample)
MX (1) MX2011000507A (enExample)
MY (1) MY155377A (enExample)
NZ (3) NZ596171A (enExample)
PT (1) PT2966091T (enExample)
RU (2) RU2539765C2 (enExample)
WO (1) WO2010009346A2 (enExample)
ZA (1) ZA201100398B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2685823T3 (es) 2008-07-16 2018-10-11 Baylor Research Institute Anticuerpos antagonistas anti-CD40
AU2009286247A1 (en) * 2008-08-29 2010-03-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a CD40 agonist to a tumor draining lymph node of a subject
JP2012520073A (ja) 2009-03-10 2012-09-06 ベイラー リサーチ インスティテュート 抗原提示細胞ターゲティングワクチン
EP2406286B1 (en) 2009-03-10 2016-05-18 Baylor Research Institute Anti-cd40 antibodies and uses thereof
CN105837691B (zh) * 2009-03-10 2021-06-29 贝勒研究院 靶向抗原呈递细胞的癌症疫苗
EP2477655A4 (en) 2009-09-14 2014-02-12 Baylor Res Inst VACCINES TREATED ON LANGERHANS CELLS
JP5628544B2 (ja) * 2010-04-07 2014-11-19 株式会社豊田中央研究所 クロストリジウム・サーモセラム由来のタンパク質複合体を構築するためのタンパク質及びその利用
US20110274653A1 (en) 2010-05-07 2011-11-10 Baylor Research Institute Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+ t cells
TWI506035B (zh) * 2010-08-13 2015-11-01 Baylor Res Inst 以直接針對抗原呈現細胞之抗體的標靶佐劑為主之新穎疫苗佐劑
US20120128710A1 (en) * 2010-11-02 2012-05-24 Baylor Research Institute Enhancement of Pathogen-Specific Memory Th17 Cell Responses
TW201247706A (en) * 2011-03-08 2012-12-01 Baylor Res Inst Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
CA2831294A1 (en) * 2011-03-25 2012-10-04 Baylor Research Institute Compositions and methods to immunize against hepatitis c virus
CN103635488B (zh) * 2011-04-29 2016-12-14 埃派斯进有限公司 抗-cd40抗体及其使用方法
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
WO2014031984A1 (en) * 2012-08-24 2014-02-27 Baylor Research Institute Immunological detection methods and compositions
WO2014039840A1 (en) * 2012-09-07 2014-03-13 Baylor Research Institute Hiv vaccine compositions and methods
EP2914627B1 (en) 2012-10-30 2021-04-07 Apexigen, Inc. Anti-cd40 antibodies and methods of use
EP3013362B1 (en) 2013-06-28 2021-08-04 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
AU2015204503B2 (en) 2014-01-13 2020-07-09 Baylor Research Institute Novel vaccines against HPV and HPV-related diseases
EA201790024A1 (ru) 2014-07-11 2017-07-31 Джилид Сайэнс, Инк. Модуляторы toll-подобных рецепторов для лечения вич
CN105821029A (zh) * 2015-01-04 2016-08-03 彭霞 异源融合基因修饰的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法
CN105821030A (zh) * 2015-01-04 2016-08-03 彭霞 表达α1，3半乳糖转移酶的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法
US20180356398A1 (en) 2017-06-09 2018-12-13 Fujifilm Corporation Living tissue model device, vascular wall model, vascular wall model device and method of evaluating test substance
WO2019031939A2 (ko) 2017-08-10 2019-02-14 주식회사 굳티셀 암 치료를 위한 t 세포의 활성화 방법
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
JP2022519378A (ja) 2019-02-08 2022-03-23 グッド ティー セルズ、 インコーポレイテッド がん治療のためのｔ細胞の活性化方法
WO2020193718A1 (en) 2019-03-27 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Recombinant proteins with cd40 activating properties
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
EP4058058A1 (en) 2019-11-14 2022-09-21 Aelix Therapeutics S.L. Dosage regimens for vaccines
CN114787181A (zh) * 2019-11-21 2022-07-22 Inserm(法国国家健康医学研究院) 用抗pd-1/il-15免疫细胞因子靶向pd-1的新型免疫疗法
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
JP2023528017A (ja) 2020-05-26 2023-07-03 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）ポリペプチドおよびワクチン目的でのその使用
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
KR20230107260A (ko) 2020-11-12 2023-07-14 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Sars-cov-2 스파이크 단백질의 수용체-결합 도메인에 접합되거나 융합된 항체, 및 백신 목적을 위한 이의 용도
GB202019879D0 (en) * 2020-12-16 2021-01-27 Ucl Business Ltd Polypeptide
CA3205280A1 (en) 2020-12-23 2022-06-30 Inserm (Institut National De La Sante Et De La Recherche Medicale) Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells
MX2023008986A (es) 2021-01-29 2023-08-15 Inst Nat Sante Rech Med Polipeptidos antigenicos de chlamydia trachomatis y usos de los mismos con fines de vacuna.
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
KR20240103030A (ko) 2021-11-17 2024-07-03 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 범용 사르베코바이러스 백신
WO2024074571A1 (en) 2022-10-05 2024-04-11 Institut National de la Santé et de la Recherche Médicale Dc-targeting vaccine against nipah virus infection
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3949064A (en) 1973-10-26 1976-04-06 Baxter Laboratories, Inc. Method of detecting antigens or antibodies
US4174384A (en) 1975-06-30 1979-11-13 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
DK8189A (da) 1988-01-12 1989-07-13 Bunge Australia Antigen-antistof-konjugater, deres fremstilling og anvendelse
US6054312A (en) * 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
WO1999057155A1 (en) 1998-05-01 1999-11-11 The Procter & Gamble Company Laundry detergent and/or fabric care compositions comprising a modified antimicrobial protein
AU4954899A (en) 1998-06-26 2000-01-17 Trustees Of Dartmouth College Methods and compositions for modulating antigen-specific immunological (humoral)responses by targeting such antigen to apcs in conjunction with anti-cd40 ligan d administration
JP2000157282A (ja) 1998-11-30 2000-06-13 Toyota Central Res & Dev Lab Inc 酵素配列複合体及び固定化酵素配列複合体とそれらの製造方法、担体分子及び酵素
EP1267907A1 (en) * 2000-03-23 2003-01-02 Akzo Nobel N.V. Use of mia in immunotherapy
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US20050013810A1 (en) 2001-05-08 2005-01-20 Waller Edmund K Regulating immune response using dendritic cells
GB0118367D0 (en) * 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
RU2312896C2 (ru) * 2001-09-20 2007-12-20 Глаксо Груп Лимитед Последовательность нуклеиновой кислоты, кодирующая белок gag вич-1, способ получения указанной последовательности, вектор, содержащий ее, белок, кодируемый ею, фармацевтическая композиция и их применение для профилактики и/или лечения вич-инфекции и спида
EP1441030A4 (en) * 2001-10-11 2007-08-15 Katakura Ind Co Ltd PROCESS FOR CLEANING A RECOMBINANT FUSION PROTEIN AND METHOD FOR PRODUCING PROTEIN THEREWITH
WO2003046012A1 (en) 2001-11-30 2003-06-05 Crucell Holland B.V. Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation
EP2258712A3 (en) 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
JP2004236504A (ja) 2003-02-03 2004-08-26 Toyota Central Res & Dev Lab Inc 酵素配列複合体及び固定化酵素配列複合体とそれらの製造方法、担体分子及び酵素
JP2005143444A (ja) * 2003-11-19 2005-06-09 Lion Corp キメラ酵素及び洗浄剤組成物
AU2005269716B2 (en) * 2004-07-20 2011-01-27 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
US20080063656A1 (en) 2004-08-09 2008-03-13 Emini Emilio A Adenoviral Vector Compositions
NZ555907A (en) * 2004-11-16 2009-12-24 Aeras Global Tb Vaccine Found Multivalent vaccines comprising recombinant viral vectors
EP1752533A1 (en) * 2005-08-12 2007-02-14 Institut National de la Recherche Agronomique Fusion proteins between plant cell-wall degrading enzymes, and their uses
WO2007103048A2 (en) 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
ES2685823T3 (es) * 2008-07-16 2018-10-11 Baylor Research Institute Anticuerpos antagonistas anti-CD40

Also Published As

Publication number Publication date
AU2009270771B2 (en) 2012-08-23
ES2890230T3 (es) 2022-01-18
RU2012153053A (ru) 2014-06-20
CA2730742A1 (en) 2010-01-21
EP2966091A1 (en) 2016-01-13
ES2685823T3 (es) 2018-10-11
MY155377A (en) 2015-10-15
PT2966091T (pt) 2018-07-26
WO2010009346A3 (en) 2010-04-29
ZA201100398B (en) 2011-10-26
US20100135994A1 (en) 2010-06-03
AU2009270771A1 (en) 2010-01-21
EP3388450A1 (en) 2018-10-17
BRPI0915915A2 (pt) 2019-09-24
JP5984388B2 (ja) 2016-09-06
EP2307048A2 (en) 2011-04-13
RU2011105119A (ru) 2012-08-27
JP2011528233A (ja) 2011-11-17
CN102625714B (zh) 2015-08-19
CA2730742C (en) 2017-05-23
DK2966091T3 (en) 2018-07-30
KR20110036618A (ko) 2011-04-07
KR20130081721A (ko) 2013-07-17
CN102625714A (zh) 2012-08-01
AP2011005541A0 (en) 2011-02-28
EP3388450B1 (en) 2021-07-07
JP2015071598A (ja) 2015-04-16
EP2307048A4 (en) 2012-02-29
EP2966091B1 (en) 2018-04-25
MX2011000507A (es) 2011-05-24
IL210646A0 (en) 2011-03-31
WO2010009346A8 (en) 2010-08-19
KR101548143B1 (ko) 2015-08-28
RU2539765C2 (ru) 2015-01-27
WO2010009346A2 (en) 2010-01-21
NZ594540A (en) 2012-01-12
JP6109800B2 (ja) 2017-04-05
NZ590628A (en) 2012-03-30
US9109011B2 (en) 2015-08-18

Similar Documents

Publication Publication Date Title
NZ596171A (en) Hiv vaccine based on targeting maximized gag and nef to dendritic cells
AU2016204319A1 (en) Methods and compositions for producing squalene using yeast
WO2012068017A3 (en) Fuel cell system with grid independent operation and dc microgrid capability
NZ593639A (en) Agents that engage antigen - presenting cells through dendritic cell asialoglyco-protein receptor (dc - asgpr)
MX2011008581A (es) Salida de planta de energia fotovoltaica.
WO2011119912A3 (en) Computing device with remote contact list
MY159971A (en) Multipotent/pluripotent cells and methods
NZ602220A (en) Antibodies with ph dependent antigen binding
SG10201809901SA (en) Generating Pluripotent Cells De Novo
SG10201804330YA (en) Engineered high-affinity human t cell receptors
EP2554669A4 (en) NEW ANTIBODY WITH ITS INTRODUCED MODIFICATION CENTER AND ANTIBODY FRAGMENT
IN2012DN00356A (enExample)
AU336708S (en) Part of a vacuum cleaner
PH12014501019A1 (en) Kit comprising serum replacement and labile factors
GB2518305A (en) Energy Harvesting System
MX2012014796A (es) Proceso para preparar 4-hidroxipiridinas.
GB201102108D0 (en) Diagnostic method
WO2009021163A3 (en) Enhancing gene transfer
AU335851S (en) A plate
ES2479540T3 (es) Células, construcciones de ácidos nucleicos, células que comprenden dichas construcciones y métodos de utilización de dichas células en el tratamiento de enfermedades
ATE532867T1 (de) B-zellen-toleranzinduktion
GB0905800D0 (en) Hardware reset
IN2012DN01293A (enExample)
WO2010096693A3 (en) Methods and materials for generating t cells
CN202276869U (zh) 一种皮带

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 16 JUL 2016 BY CPA GLOBAL

Effective date: 20130531

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 JUL 2017 BY CPA GLOBAL

Effective date: 20160603

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 JUL 2018 BY CPA GLOBAL

Effective date: 20170601

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 JUL 2019 BY CPA GLOBAL

Effective date: 20180531

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 JUL 2020 BY COMPUTER PACKAGES INC

Effective date: 20190702

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 JUL 2021 BY COMPUTER PACKAGES INC

Effective date: 20200701

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 JUL 2022 BY COMPUTER PACKAGES INC

Effective date: 20210630

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 JUL 2023 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD

Effective date: 20220711

LAPS Patent lapsed